ArticleNature communications2018
HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Vaccination induces HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2022Trial
- Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.Nature communications · 2024Article
- Synthesis and Structure Optimization of Star Copolymers as Tunable Macromolecular Carriers for Minimal Immunogen Vaccine Delivery.Bioconjugate chemistry · 2024Article
- Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction.Cell host & microbe · 2024Article
- Structural basis for breadth development in the HIV-1 V3-glycan targeting DH270 antibody clonal lineage.Nature communications · 2023Article
- Structure-Based Stabilization of SOSIP Env Enhances Recombinant Ectodomain Durability and Yield.Journal of virology · 2023Article
- Analysis of two cooperating antibodies unveils immune pressure imposed on HIV Env to elicit a V3-glycan supersite broadly neutralizing antibody lineage.Frontiers in immunology · 2022Article
- How Antibodies Recognize Pathogenic Viruses: Structural Correlates of Antibody Neutralization of HIV-1, SARS-CoV-2, and Zika.Viruses · 2021Review
- Review
- Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations.Cell reports · 2021Article
- Double Arylation of the Indole Side Chain of Tri- and Tetrapodal Tryptophan Derivatives Renders Highly Potent HIV-1 and EV-A71 Entry Inhibitors†.Journal of medicinal chemistry · 2021Article
- Article
- Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies.Cell · 2021Article
- The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans.ACS chemical biology · 2020Article
- Article
- The Effects of Framework Mutations at the Variable Domain Interface on Antibody Affinity Maturation in an HIV-1 Broadly Neutralizing Antibody Lineage.Frontiers in immunology · 2020Article
- Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.Science (New York, N.Y.) · 2019Article
- Glycopeptides and -Mimetics to Detect, Monitor and Inhibit Bacterial and Viral Infections: Recent Advances and Perspectives.Molecules (Basel, Switzerland) · 2019Review
- Antibody responses to the HIV-1 envelope high mannose patch.Advances in immunology · 2019Review
- Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.Retrovirology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 1 country.
Daniela FeraLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA. dfera1@swarthmore.edu.ORCID http://orcid.org/0000-0002-1706-9288
Matthew S LeeLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Kevin WieheDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
R Ryan MeyerhoffDuke Human Vaccine Institute, Durham, NC, 27710, USA.
Alessandro PiaiDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, 02115, USA.ORCID http://orcid.org/0000-0002-5264-1980
Mattia BonsignoriDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
Baptiste AussedatDepartment of Bioorganic Chemistry, Sloan Kettering Institute, New York, NY, 10065, USA.
William E WalkowiczDepartment of Bioorganic Chemistry, Sloan Kettering Institute, New York, NY, 10065, USA.
Therese TonDepartment of Biology, Swarthmore College, Swarthmore, PA, 19081, USA.
Jeffrey O ZhouDepartment of Chemistry and Biochemistry, Swarthmore College, Swarthmore, PA, 19081, USA.
Samuel DanishefskyDepartment of Bioorganic Chemistry, Sloan Kettering Institute, New York, NY, 10065, USA.
Barton F HaynesDepartment of Medicine, Duke University School of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
Stephen C HarrisonLaboratory of Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA, 02115, USA.
Duke University · USBoston Children's Hospital · USKettering University · USSwarthmore College · USHarvard University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MVirus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7MVirus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2017 to 2026
$40.7MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2MOverall EvaluationP41GM103403 · NIGMS · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2012 to 2017
$14.3MPixel Array Detector for X-ray CrystallographyS10RR029205 · NCRR · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2010 to 2010
$1.8MData commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598kInterplay between antibody affinity maturation and HIV evolution in a single hostF32AI116355 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI FERA, DANIELA · 2015 to 2016
$105kNovel mouse model of HIV broad neutralizing antibody inductionF30AI122982 · NIAID · DUKE UNIVERSITY · PI MEYERHOFF, ROBERT RYAN · 2016 to 2017
$79kHoward Hughes Medical InstituteNCI NIH HHS P30 CA008748NCRR NIH HHS S10 RR029205NIAID NIH HHS F30 AI122982NIAID NIH HHS F32 AI116355NIAID NIH HHS P01 AI131251NIAID NIH HHS UM1 AI100645NIGMS NIH HHS P41 GM103403NIGMS NIH HHS T32 GM007171NIH HHS S10 OD018164
Abstract
HIV-1 envelope (Env) mimetics are candidate components of prophylactic vaccines and potential therapeutics. Here we use a synthetic V3-glycopeptide ("Man
Indexed as
Amino Acid MotifsAntibodies, NeutralizingEpitope MappingEpitopesGene Products, envHIV-1HIV AntibodiesHIV InfectionsHumansModels, MolecularMutationAntibodies, NeutralizingEpitopesGene Products, envHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.